Creative Medical Technology Holdings Management

Management Kriterienprüfungen 2/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Tim Warbington

Geschäftsführender

US$522.6k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	63.1%
Amtszeit als Geschäftsführer	8.8yrs
Eigentum des Geschäftsführers	0.7%
Durchschnittliche Amtszeit des Managements	keine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.9yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Tim Warbington im Vergleich zu den Einnahmen von Creative Medical Technology Holdings verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Sep 30 2024	n/a	n/a	-US$5m
Jun 30 2024	n/a	n/a	-US$6m
Mar 31 2024	n/a	n/a	-US$5m
Dec 31 2023	US$523k	US$330k	-US$5m
Sep 30 2023	n/a	n/a	-US$10m
Jun 30 2023	n/a	n/a	-US$9m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$469k	US$330k	-US$10m
Sep 30 2022	n/a	n/a	-US$8m
Jun 30 2022	n/a	n/a	-US$9m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	US$99k	US$99k	US$19m

Vergütung im Vergleich zum Markt: TimDie Gesamtvergütung ($USD522.62K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD653.16K).

Entschädigung vs. Einkommen: TimDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Tim Warbington (62 yo)

8.8yrs

Amtszeit

US$522,620

Vergütung

Mr. Timothy Warbington, also known as Tim, is Co-Founder of Creative Medical Technology Holdings, Inc. and serves as its Chief Executive Officer since February 2016 and serves as its President since May 18...

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Timothy Warbington	Co-Founder	8.8yrs	US$522.62k	0.70% $ 25.3k
Donald Dickerson	Senior VP	8.8yrs	US$467.25k	0.00097% $ 35.1
Susan Snow	Independent Director	3yrs	US$120.00k	keine Daten
Boris Reznik	Member of Scientific Advisory Board	3.9yrs	keine Daten	keine Daten
Camillo Ricordi	Member of Scientific Advisory Board	3.6yrs	keine Daten	keine Daten
Santosh Kesari	Member of Scientific Advisory Board	8yrs	keine Daten	keine Daten
Michael Finger	Independent Director	3yrs	US$80.00k	0.11% $ 3.8k
Timothy Henry	Member of Scientific Advisory Board	6.5yrs	keine Daten	keine Daten
Bruce Urdang	Independent Director	3yrs	US$100.00k	keine Daten

3.9yrs

Durchschnittliche Betriebszugehörigkeit

66yo

Durchschnittliches Alter

Erfahrener Vorstand: CELZDie Vorstandsmitglieder gelten als erfahren (3.9 Jahre durchschnittliche Amtszeit).

Unternehmensanalyse und Finanzdaten Status

Daten	Zuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse	2024/12/23 23:11
Aktienkurs zum Tagesende	2024/12/23 00:00
Gewinne	2024/09/30
Jährliche Einnahmen	2023/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

Paket	Daten	Zeitrahmen	Beispiel US-Quelle ^*
Finanzdaten des Unternehmens	10 Jahre	Gewinn- und Verlustrechnung Kapitalflussrechnung Bilanz	SEC-Formular 10-K SEC-Formular 10-Q
Konsensschätzungen der Analysten	+3 Jahre	Finanzielle Vorausschau Kursziele der Analysten	Analysten Research Berichte Blue Matrix
Marktpreise	30 Jahre	Aktienkurse Dividenden, Splits und Aktionen	ICE-Marktdaten SEC-Formular S-1
Eigentümerschaft	10 Jahre	Top-Aktionäre Insiderhandel	SEC-Formular 4 SEC-Formular 13D
Verwaltung	10 Jahre	Das Führungsteam Direktorium	SEC-Formular 10-K SEC-Formular DEF 14A
Wichtige Entwicklungen	10 Jahre	Ankündigungen des Unternehmens	SEC-Formular 8-K

^* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie hier mehr.

Analysemodell und Schneeflocke

Einzelheiten zum Analysemodell, das zur Erstellung dieses Berichts verwendet wurde, finden Sie auf unserer Github-Seite. Wir haben auch Anleitungen zur Verwendung unserer Berichte und Tutorials auf Youtube.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf .

Analysten-Quellen

Creative Medical Technology Holdings, Inc. wird von 1 Analysten beobachtet. 1 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

Analyst	Einrichtung
Jonathan Aschoff	Roth MKM

Creative Medical Technology Holdings Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

High number of new and inexperienced directors

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Recent updates

Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment

New minor risk - Shareholder dilution

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

Creative Medical Technology Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $1.85 million.

New minor risk - Share price stability

Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin

Creative Medical Technology Holdings, Inc., Annual General Meeting, Jul 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Creative Medical Technology Holdings Inc. Announces FDA Authorization for Type 1 Diabetes Prevention Therapy Under Expanded Access

Creative Medical Technology Holdings, Inc. Receives Clearance from the FDA to Conduct a Phase 1/2 Clinical Trial Using Their Innovative StemSpine Treatment Known as AlloStem

New major risk - Financial position

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 20, 2023

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Stemspine(R) Using Allostem(Tm) (Celz-201-Ddt) Novel Cell Therapy to Treat Chronic Lower Back Pain

Creative Medical Technology Holdings Receives FDA Clearance to Initiate A Phase 1/2 Clinical Trial of Stemspine® Using Allostem™ (Celz-201-Ddt) for the Treatment of Chronic Lower Back Pain

Creative Medical Technology Holdings Regains Compliance with Nasdaq Listing Requirements

Creative Medical Technology Holdings, Inc. (NasdaqCM:CELZ) announces an Equity Buyback for $2 million worth of its shares.

Creative Medical Technology Holdings Announces Successful Completion of the First Phase of Its Program with Greenstone Biosciences, Inc. to Develop Next Generation iPSC Pipeline for ImmCelz(R) Immunotherapy Platform

Creative Medical Technology Holdings, Inc. Announces Next Milestone Achievements in ImmCelz Platform Development

Creative Medical Technology Holdings Announces Positive Top-Line Study Results for Chronic Lower Back Pain Utilizing its StemSpine® Procedure Using AlloStem™ Allogenic Cell Line

Creative Medical Technology Holdings, Inc. Announces Positive Three-Year Follow-Up Data for the Company's Stemspine Pilot Study

Creative Medical Technology Holdings, Inc. Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of Novel Cell Therapy for the Treatment of Type 1 Diabetes

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Fda Clearance of Investigational New Drug (Ind) Application for Allostem(Tm), A Novel Cell Therapy for the Treatment of Type 1 Diabetes

Creative Medical Technology Holdings, Inc., Annual General Meeting, Dec 19, 2022

Creative Medical Technology Holdings, Inc. Develops AlloStem Clinical Cell Line

Creative Medical Technology Announces Positive Top-Line Results for OvaStem® Pilot Study

Creative Medical Technology Holdings Receives Non-Compliance Notice from Nasdaq

Creative Medical Technology Holdings, Inc. announced that it has received $17.000001 million in funding

High number of new and inexperienced directors

Creative Medical Technology Holdings, Inc. Announces Progress in Developing a Reproducible Clinical Grade of the Company's ImmCelz® Product

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

Creative Medical Technology Appoints Sahil Nock as Chief Commercial Officer

High number of new and inexperienced directors

Creative Medical Technology Holdings Deleted from Other OTC

Less than half of directors are independent

Creative Medical Technology Holdings, Inc. announced that it has received $3.78775 million in funding

Creative Medical Technology Holdings, Inc. announced that it expects to receive $3.788 million in funding

Creative Medical Technology Holdings Identifies Synergy Between Immcelz® Regenerative Immunotherapy and Myeloid Suppressor Cells in Treatment of Type 1 Diabetes

Creative Medical Technology Holdings Expands Neurological Application of ImmCelz® into Parkinson's Disease

FDA Responds to Creative Medical Technology Holdings, Inc. Regarding its ImmCelz® IND for Stroke Treatment

Creative Medical Technology Holdings, Inc. Announces Fda Acknowledgment of Ind Application for Immcelz® to Treat Stroke

Creative Medical Technology Holdings Publishes Efficacy in Pain Reduction and Mobility in Patients with Disc Degenerative Disc Using Stemspine® Personalized Adult Stem Cell Therapy

Creative Medical Technology Holdings Provides Update on ImmCelz® FDA Application

Creative Medical Technology Holdings Files Patent on Prevention of Organ Transplant Rejection Using ImmCelz®

Creative Medical Technology Holdings Identifies Cellular Mechanism of Patented Ovastem® Female Infertility/Ovarian Failure Treatment

Creative Medical Technology Holdings, Inc. Announces the Recruitment of Dr. Caigan Du to the Scientific Advisory Board

Creative Medical Technology Holdings Identifies and Files Patent on Novel Mechanism of Immcelz® Therapeutic Activity

Creative Medical Technology Holdings Inc. Recruits Dr. Boris Reznik to the Scientific Advisory Board

Creative Medical Technology Holdings Inc. Files Investigational New Drug Application with FDA for Treatment of Stroke using ImmCelz® Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Patent Filing Based on Preclinical Data in Model of Heart Attack Using ImmCelz Regenerative Immunotherapy

Creative Medical Technology Holdings Announces Successful Application of ImmCelz® Immunotherapy for Treatment of Stroke

Creative Medical Technology Holdings Files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz® Cellular Immunotherapy

Creative Medical Technology Holdings Reports Positive Preclinical Data on ImmCelz® Immunotherapy Product in Rheumatoid Arthritis Model

Analyse der Geschäftsführervergütung

Geschäftsführer

Amtszeit

Vergütung

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Unternehmensanalyse und Finanzdaten Status

Datenquellen

Analysemodell und Schneeflocke

Metriken für Industrie und Sektor

Analysten-Quellen